Atom Investors’s C4 Therapeutics CCCC Stock Holding History

Atom Investors’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.7M	Buy	364,351 +228,304	+168%	+$781K	0.15%	209
2026 Q1	$358K	Buy	136,047 +31,083	+30%	+$73.2K	0.03%	526
2025 Q4	$200K	Buy	+104,964	New	+$249K	0.02%	502
2025 Q3	–	Sell	-190,182	Closed	-$272K	–	623
2025 Q2	$272K	Sell	190,182 -78,650	-29%	-$114K	0.02%	457
2025 Q1	$430K	Buy	268,832 +167,148	+164%	+$499K	0.05%	312
2024 Q4	$366K	Buy	+101,684	New	+$506K	0.05%	345
2024 Q3	–	Sell	-332,620	Closed	-$1.54M	–	481
2024 Q2	$1.54M	Buy	332,620 +16,374	+5%	+$97.7K	0.15%	191
2024 Q1	$2.58M	Buy	+316,246	New	+$2.45M	0.32%	89
2022 Q3	–	Sell	-27,512	Closed	-$207K	–	299
2022 Q2	$207K	Buy	+27,512	New	+$242K	0.09%	181

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Atom Investors's CCCC Position: Q2 2026 in Review

Atom Investors increased its C4 Therapeutics (CCCC) stake by 168% in Q2 2026, buying an estimated $781K and bringing the position to 364,351 shares worth $1.7M. The position accounts for 0.15% of the portfolio, ranked #209.

Atom Investors first reported a position in CCCC in Q2 2022 and has held it in 9 quarters since. The position peaked at $2.58M in Q1 2024. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

Atom Investors held 364,351 shares of C4 Therapeutics worth $1.7M as of Q2 2026.
Atom Investors bought 228,304 C4 Therapeutics shares in Q2 2026, an estimated $781K.
C4 Therapeutics made up 0.15% of Atom Investors's portfolio in Q2 2026, its #209 holding.
Atom Investors first reported a position in C4 Therapeutics in Q2 2022 and has held it in 9 quarters since.
Atom Investors's C4 Therapeutics position peaked at $2.58M in Q1 2024.
147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Atom Investors's 13F filing for Q2 2026, filed 14 Aug 2026.